In yesterday’s Wall Street session, Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares traded at $1.36, unchanged from the previous session.
9 analysts cover Ginkgo Bioworks Holdings Inc (NYSE:DNA), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $1.25, we find $3.00. Given the previous closing price of $1.36, this indicates a potential upside of 120.59 percent. DNA stock price is now -9.69% away from the 50-day moving average and -16.42% away from the 200-day moving average. The market capitalization of the company currently stands at $2.72B.
The stock has received a hold rating from 4 analysts and a buy rating from 3. Brokers who have rated the stock have averaged $3.38 as their price target over the next twelve months.
With the price target reduced from $3.50 to $2.50, Raymond James Downgraded its rating from Outperform to Mkt Perform for Ginkgo Bioworks Holdings Inc (NYSE: DNA).
In other news, Kelly Jason R, insider sold 100,000 shares of the company’s stock on Dec 07. The stock was sold for $131,300 at an average price of $1.31. Upon completion of the transaction, the insider now directly owns 4,494,680 shares in the company, valued at $6.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 07, Shetty Reshma P. sold 37,650 shares of the business’s stock. A total of $49,510 was realized by selling the stock at an average price of $1.31. This leaves the insider owning 12,449,844 shares of the company worth $16.93 million. Insiders disposed of 29,843,108 shares of company stock worth roughly $40.59 million over the past 1 year. A total of 34.03% of the company’s stock is owned by insiders.
On Monday morning Ginkgo Bioworks Holdings Inc (NYSE: DNA) stock kicked off with the opening price of $1.3500. During the past 12 months, Ginkgo Bioworks Holdings Inc has had a low of $1.12 and a high of $2.55. As of last week, the company has a debt-to-equity ratio of 0.32, a current ratio of 6.78, and a quick ratio of 6.78. The fifty day moving average price for DNA is $1.5060 and a two-hundred day moving average price translates $1.6271 for the stock.
The latest earnings results from Ginkgo Bioworks Holdings Inc (NYSE: DNA) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.16, missing analysts’ expectations of -$0.09 by -0.07. This compares to -$0.41 EPS in the same period last year. The net profit margin was -272.30% and return on equity was -63.83% for DNA. The company reported revenue of $55.43 million for the quarter, compared to $66.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -16.52 percent. For the current quarter, analysts expect DNA to generate $42.53M in revenue.
Ginkgo Bioworks Holdings Inc(DNA) Company Profile
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
